Statistical Thinking for Non-Statisticians in Drug Regulation

Statistical Thinking for Non-Statisticians in Drug Regulation

Volumn , Issue , 2012, Pages

  Kay, Richard ^a  

^a Statistics for the Pharmaceutical Industry   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891584920     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118451885     Document Type: Book

References (113)

1. Altman DG (1991) Practical Statistics for Medical Research London: Chapman & Hall
2. Altman DG (1998) 'Confidence intervals for the number needed to treat' British Medical Journal, 317, 1309-1312
3. Altman DG, Schultz KF, Moher D, Egger M et al. for the CONSORT Group (2001) 'The revised CONSORT statement for reporting randomized trials: explanation and elaboration' Annals of Internal Medicine, 134, 663-694
4. Arani RB, Soong S-J, Weiss HL, Wood MJ et al. (2001) 'Phase specific analysis of herpes zoster associated pain data: a new statistical approach' Statistics in Medicine, 20, 2429-2439
5. Bedikian AY, Millward M, Pehamberger H, Conry R et al. (2006) 'Bcl-2 Antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group' Journal of Clinical Oncology, 24, 4738-4745
6. Bland M (2004) 'Cluster randomised trials in the medical literature: two bibliometric surveys' BMC Medical Research Methodology, 4, 21
7. Bolland K and Whitehead J (2000) 'Formal approaches to safety monitoring of clinical trials in life-threatening conditions' Statistics in Medicine, 19, 2899-2917
8. Breslow NE and Day NE (1994) Statistical Methods in Cancer Research, Volume II: The Design and Analysis of Cohort Studies IARC Publications, 82, New York: Oxford University Press
9. Brodie MJ, Richens A, Yuen AWC, for UK Lamotrigine/Carbamazepine Monotherapy Trial Group (1995) 'Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy' The Lancet, 345, 476-479
10. Brodie MJ and Whitehead J (2006) 'Active control comparisons: the ideal trial design' Epilepsy Research, 68, 70-73
11. Byar DP (1980) 'Why data bases should not replace randomised trials' Biometrics, 36, 337-342
12. Campbell MJ, Donner A and Klar N (2007) 'Developments in cluster randomised trials and Statistics in Medicine' Statistics in Medicine, 26, 2-19
13. Coronary Drug Project Research Group (1980) 'Influence and adherence to treatment and response of cholesterol on mortality in the coronary drug project' New England Journal of Medicine, 303, 1038-1041
14. Cox DR (1972) 'Regression models and life tables (with discussion)' Journal of the Royal Statistical Society, B, 74, 187-220
15. Crawford ED, Eisenberger MA, McLoed DG, Spaulding JT et al. (1989) 'A controlled trial of leuprolide with and without flutamide in prostatic cancer' New England Journal of Medicine, 321, 419-424
16. Ebbutt AF and Frith L (1998) 'Practical issues in equivalence trials' Statistics in Medicine, 17, 1691-1701
17. Eggar M and Smith D (1998) 'Meta-analysis bias in location and selection of studies' British Medical Journal, 316, 61-66
18. Eggar M, Smith GD, Schneider M and Minder C (1997) 'Bias in meta-analysis detected by a simple, graphical test' British Medical Journal, 315, 629-634
19. Ellenberg SS, Fleming TR and DeMets DL (2003) 'Data Monitoring Committees in Clinical Trials: A Practical Perspective' New York: John Wiley & Sons, Inc
20. Fleiss JL (1993) 'The statistical basis of meta-analysis' Statistical Methods in Medical Research, 2, 121-145
21. Fleming TR and DeMets DL (1996) 'Surrogate end points in clinical trials: Are we being misled?' Annals of Internal Medicine, 125, 605-613
22. Ford I, Norrie J and Ahmedi S (1995) 'Model inconsistency, illustrated by the Cox Proportional Hazards model' Statistics in Medicine, 14, 735-746
23. Gardner MJ and Altman DG (1989) 'Estimation rather than hypothesis testing: confidence intervals rather than p-values' In: Statistics with Confidence (eds MJ Gardner and DG Altman), London: British Medical Journal, 6-19
24. Gehan EA (1969) 'Estimating survival functions from the life table' Journal of Chronic Diseases, 21, 629-644
25. Gillings D and Koch G (1991) 'The application of the principle of intention-to-treat analysis of clinical trials' Drug Information Journal, 25, 411-424
26. Greenwood M (1926) 'The errors of sampling of the survivorship tables' Reports on Public Health and Statistical Subjects, No. 33, Appendix 1. London: HMSO
27. Grieve AP (2003) 'The number needed to treat: a useful clinical measure or a case of the Emperor's new clothes?' Pharmaceutical Statistics, 2, 87-102
28. Haybittle JL (1971) 'Repeated assessment of results in clinical trials of cancer treatment' British Journal of Radiology, 44, 793-797
29. Helsinki Declaration (2004) 'Ethical Principles for Medical Research Involving Human Subjects' WMA General Assembly, Tokyo 2004
30. Hennerici MG, Kay R, Bogousslavsky J, Lenzi JM, Orgogozo M, for the ESTAT Investigators (2006) 'Intravenous ancrod for acute ischemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial.' The Lancet, 368, 1871-1878
31. Jensen MP, Karoly P, O'Riordan EF, Bland F and Burns RS (1989) 'The subjective experience of pain. An assessment of the utility of 10 indices' The Clinical Journal of Pain, 5, 153-159
32. Jones B, Jarvis P, Lewis JA and Ebbutt AF (1996) 'Trials to assess equivalence: the importance of rigorous methods' British Medical Journal, 313, 36-39
33. Julious SA (2004) 'Using confidence intervals around individual means to assess statistical significance between two means' Pharmaceutical Statistician, 3, 217-222
34. Julious SA (2005) 'Why do we use pooled variance analysis of variance?' Pharmaceutical Statistics, 4, 3-5
35. Julious SA and Mullee MA (1994) 'Confounding and Simpson's Paradox' British Medical Journal, 309, 1480-1481
36. Kaplan EL and Meier P (1958) 'Non-parametric estimation from incomplete observations' Journal of the American Statistical Association, 53, 457-481
37. Kaul S and Diamond GA (2006) 'Good enough: a primer on the analysis and interpretation of non-inferiority trials' Annals of Internal Medicine, 145, 62-69
38. Kay R (1995) 'Some fundamental statistical concepts in clinical trials and their application in herpes zoster' Antiviral Chemistry and Chemotherapy, 6, Supplement 1, 28-33
39. Kay R (2004) 'An explanation of the hazard ratio' Pharmaceutical Statistics, 3, 295-297
40. Kay R (2006) Letter to the Editor on 'Phase specific analysis of herpes zoster associated pain data: a new statistical approach' Statistics in Medicine, 25, 359-360
41. Landis RJ, Heyman ER and Koch GG (1978) 'Average partial association in three-way contingency tables: A review and discussion of alternative tests' International Statistical Review, 46, 237-254
42. Lewis JA (2002) 'The European regulatory experience' Statistics in Medicine, 21, 2931-2938
43. Lewis JA (2004) 'In defence of the dichotomy.' Pharmaceutical Statistics, 3, 77-79
44. Li Z, Chines AA and Meredith MP (2004) 'Statistical validation of surrogate endpoints: Is bone density a valid surrogate for fracture?' Journal of Musculoskeletal Neuron Interaction, 4, 64-74
45. Liu M, Wei L and Zhang J (2006) 'Review of guidelines and literature for handling missing data in longitudinal clinical trials with a case study' Pharmaceutical Statistics, 5, 7-18
46. Machin D, Campbell MJ, Fayers PM and Pinol APY (1997) Statistical Tables for the Design of Clinical Trials (2nd edn) Blackwell Scientific Publications, Oxford
47. Mantel N and Haenszel W (1959) 'Statistical aspects of the analysis of data from retrospective studies of disease' Journal of the National Cancer Institute, 22, 719-748
48. Marshall RJ and Chisholm EM (1985) 'Hypothesis testing in the polychotomous logistic model with an application to detecting gastrointestinal cancer' Statistics in Medicine, 5, 337-344
49. Matthews JNS, Altman DG, Campbell MJ and Royston P (1990) 'Analysis of serial measurements in medical research' British Medical Journal, 300, 230-235
50. Meier P (1978) 'The biggest public health experiment ever: The 1954 Field Trial of the Salk Poliomyelitis Vaccine' In Statistics, A Guide to the Unknown (ed. J Tanur, F Mostellor et al.) San Fransisco: Holden Day
51. Miller DH, Khan OA, Sheremata WA, Blumhardt LD et al., for the International Natalizumab Multiple Sclerosis Trial Group (2003) 'A controlled trial of natalizumab for relapsing multiple sclerosis' New England Journal of Medicine, 348, 15-23
52. Moher D, Schulz KF and Altman DG (2001) 'The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials' Annals of Internal Medicine, 134, 657-694
53. Mulrow CD (1994) 'Rationale for systematic reviews' British Medical Journal, 309, 597-599
54. Nakamura H, Arakawa K, Itakura H, Kitabatake A et al., for the MEGA Study Group (2006) 'Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial' The Lancet, 368, 1155-1163
55. Normand S-LT (1999) 'Meta-analysis: formulating, evaluating, combining, and reporting' Statistics in Medicine, 18, 321-359
56. O'Brien PC and Fleming TR (1979) 'A multiple testing procedure for clinical trials' Biometrics, 35, 549-556
57. Okwera A, Byekwaso F, Mugerwa R, Ellner J et al. Makerere University-Case Western University Research Collaboration (1994) 'Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans.' The Lancet, 344, 1323-1328
58. Packer M, Coats AJS, Fowler MB, et al. for the Carvedilol Prospective Randomised Cumulative Survival Study Group (2001) 'Effect of carvedilol on survival in severe chronic heart failure' New England Journal of Medicine, 344, 1651-1658
59. Patel K, Kay R and Rowell L (2006) 'Comparing proportional hazards and accelerated failure time models: An application in Influenza' Pharmaceutical Statistics, 5, 213-224
60. Peto R and Peto J (1972) 'Asymptotically efficient rank invariant procedures.' Journal of the Royal Statistical Society, A, 135, 185-207
61. Peto R, Pike MC, Armitage P, Breslow NE et al. (1976) 'Design and analysis of randomised clinical trials requiring prolonged observation of each patient. I. Introduction and design' British Journal of Cancer, 34, 585-612
62. Phillips AJ and Keene ON on behalf of the PSI Adaptive Design Expert Group (2006) 'Adaptive Designs for Pivotal Trials' Pharmaceutical Statistics, 5, 61-66
63. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A et al., for the Herceptin Adjuvant (HERA) Trial Study Team (2005) 'Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer' New England Journal of Medicine, 353, 1659-1672
64. Pocock SJ (1977) 'Group sequential methods in the design and analysis of clinical trials' Biometrika, 64, 191-199
65. Pocock SJ (1983) Clinical Trials: A Practical Approach Chichester: John Wiley & Sons, Ltd
66. Pocock SJ (2004) 'A major trial needs three statisticians: why, how and who?' Statistics in Medicine, 23, 1535-1539
67. Pocock SJ, Clayton TC and Altman DG (2002) 'Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls' The Lancet, 359, 1686-1689
68. Powderly WG, Saag MS, Cloud GA, Robinson P et al., the NIAID AIDS Clinical Trials Group and the NIAID Mycosis Study Group (1992) 'A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome' New England Journal of Medicine, 326, 793-798
69. Roes KCB (2004) 'Dynamic allocation as a balancing act' Pharmaceutical Statistics, 3, 187-191
70. Rubin LJ, Badesch DB, Barst RJ, Galie N et al. for the Bosentan Randomised Trial of Endothelin Antagonist Therapy Study Group (2002) 'Bosentan theraphy for pulmonary arterial hypertension' New England Journal of Medicine, 346, 869-903
71. Rudick RA Stuart WH, Calabresi PA, Confavreux C et al. for the SENTINEL Investigators (2006) 'Natalizumab plus interferon beta-1a for relapsing multiple sclerosis' New England Journal of Medicine, 354, 911-923
72. Sargent DJ, Goldberg RM, Jacobson SD, MacDonald JS et al. (2001) 'A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients' New England Journal of Medicine, 345, 1091-1097
73. Schuirmann DJ (1987) 'A comparison of two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability' Journal of Pharmacokinetics and Biopharmaceutics, 15, 657-680
74. Senn S (1997) Statistical Issues in Drug Development Chichester: John Wiley & Sons, Ltd
75. Senn S (2002) 'Cross-Over Trials in Clinical Research (2nd edn)' Chichester: John Wiley & Sons
76. Senn S (2003) 'Disappointing dichotomies.' Pharmaceutical Statistics, 2, 239-240
77. Sherman DG, Atkinson RP, Chippendale T et al. (2000) 'Intravenous ancrod for treatment of acute ischemic stroke; the STAT study; a randomised controlled trial.' Journal of the American Medical Association, 283, 2395-2403
78. Smith GD and Eggar M (1997) Letter to the Editor The Lancet, 350, 1182
79. Stokes ME, Davis CS and Koch GG (1995) Categorical Data Analysis Using the SAS System Cary, NC: SAS Institute Inc
80. Storosum JG, van Zwieten BJ, Vermeulen HDB, Wohlfarth T et al. (2001) 'Relapse and recurrence in major depression: a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues' European Psychiatry, 16, 327-335
81. Stutchfield P, Whitaker R and Russell I, on behalf of the Antenatal Steroids for Term Elective Caesarean Section (ASTECS) Research Team (2005) 'Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial' British Medical Journal, 331, 662-667
82. van Belle G, Fisher LD, Heagerty PJ and Lumley T (2004) 'Biostatistics: A Methodology for the Health Sciences (2nd edn)' New Jersey: John Wiley & Sons
83. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E et al. for the 2NN Study Team (2004) 'Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study' The Lancet, 363, 1253-1263
84. Westlake WJ (1981) 'Bioequivalence testing - a need to rethink (Reader Reaction Response)' Biometrics, 37, 589-594
85. The Xamoterol in Severe Heart Failure Study Group (1990) 'Xamoterol in severe heart failure' The Lancet, 336, 1-6
86. ICH E3 (1995) 'Note for Guidance on Structure and Content of Clinical Study Reports'
87. ICH E9 (1998) 'Note for Guidance on Statistical Principles for Clinical Trials'
88. ICH E10 (2001) 'Note for Guidance on Choice of Control Group in Clinical Trials'
89. FDA (1992) 'Points to Consider on Clinical Development and Labeling of Anti-Infective Drug Products'
90. FDA (1998) 'Developing Antimicrobial Drugs - General Consideration for Clinical Trials'
91. FDA (2001) 'Statistical Approaches to Establishing Bioequivalence'
92. FDA (2004) 'Critical Path Initiative'
93. FDA (2005) 'Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics'
94. FDA (2006) 'Critical Path Opportunities List'
95. FDA (2006) 'Establishment and Operation of Clinical Trial Data Monitoring Committees'
96. CPMP (2000) 'Points to Consider on Switching between Superiority and Non-Inferiority'
97. CPMP (2001) 'Points to Consider on Applications with 1. Meta Analyses; 2. One Pivotal Study
98. CPMP (2001) 'Points to Consider on Missing Data'
99. CPMP (2001) 'Note for Guidance on the Investigation of Bioavailability and Bioequivalence'
100. CPMP (2002) 'Points to Consider on Multiplicity Issues in Clinical Trials'
101. CPMP (2003) 'Points to Consider on Adjustment for Baseline Covariates'
102. CHMP (2005) 'Guidance on the Choice of Non-Inferiority Margin'
103. CHMP (2005) 'Guideline on Data Monitoring Committees'
104. CHMP (2005) 'Guideline on Clinical Trials in Small Populations'
105. CHMP (2006) 'Reflection Paper on Methodological Issues in Confirmatory Clinical Trials with Flexible Design and Analysis Plan' (Draft)
106. CPMP (1997) 'Note for Guidance on Medicinal Products in the Treatment of Alzheimer's Disease'
107. CPMP (1997) 'Note for Guidance on Evaluation of New Anti-Bacterial Medicinal Products'
108. CPMP (1999) 'Note for Guidance on Clinical Evaluation of New Vaccines'
109. CPMP (2001) 'Note for Guidance on Clinical Investigation of Medicinal Products for the Treatment of Acute Stroke'
110. CPMP (2002) 'Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Asthma'
111. CPMP (2003) 'Note for Guidance on Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections'
112. CPMP (2003) 'Points to Consider on the Clinical Development of Fibrinolytic Medicinal Products in the Treatment of Patients with ST Segment Elevation Acute Myocardial Infarction (STEMI)'
113. CHMP (2006) 'Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues'